Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Read more about Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Read more about TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Read more about Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia. Read more about Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10). Read more about Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).
Management and outcomes for patients with TTP: analysis of 100 cases at a single institution. Read more about Management and outcomes for patients with TTP: analysis of 100 cases at a single institution.
Accessory splenules in autoimmune hemolytic anemia. Read more about Accessory splenules in autoimmune hemolytic anemia.
Population-based screening for anemia using first-time blood donors. Read more about Population-based screening for anemia using first-time blood donors.
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Read more about Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Experience with use of Zostavax(®) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Read more about Experience with use of Zostavax(®) in patients with hematologic malignancy and hematopoietic cell transplant recipients.
